Skip to content
Wednesday 19 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,728.04
+0.07%
DAX
26,128.36
0.00%
CAC 40
8,509.36
0.00%
STOXX 50
6,468.17
0.00%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Friday 05 February 2021 12:25 pm  |  Updated:  Friday 05 February 2021 2:29 pm

Government orders 50m doses of CureVac vaccine for new Covid mutations

By: Poppy Wood

Add as a preferred source on Google
Astrazeneca Pfizer vaccines

The government has signed a deal with German biotech firm CureVac for 50m doses of a new vaccine being developed to tackle emerging Covid mutations.

The deal will see CureVac create “new varieties of vaccines based on messenger RNA technology to be developed quickly against new strains of Covid-19 if they are needed”, the Department of Health and Social (DHSC) care said in a statement.

The agreement will also allow large-scale manufacturing of vaccines in the UK to avoid potential export delays, after a high-stakes tussle with the EU last week.

It takes the total number of vaccines ordered by the government to 457m from eight different pharmaceutical companies. So far only the Pfizer/Biontech and Astrazeneca/Oxford University vaccines are being administered to the public.

DHSC also announced today that the government is establishing an expert advisory group to identify emerging variants that may require updated or fresh vaccines.

It comes after scientists warned earlier this week that a new E484K mutation identified in the Kent, South African and Brazilian variants of coronavirus could prove resistant to existing vaccines.

The mutation is understood to have occurred spontaneously in the Kent variant — which is now the dominant strain of coronavirus across the UK — and has so far been found in 11 samples of around 200,000 that have been sequenced.

Read more

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

Scientists have warned that those who have been infected with previous Covid variants may not have immunity to the latest strain.

Dr Susan Hopkins, chief epidemiologist at Public Health England, said that existing vaccines may offer less protection against the South African variant, although they still offer a good level of immunity.

US biotech firm Moderna and British-Swedish pharma giant Astrazeneca have both said they will trial a new vaccine for the South African variant. Studies showed Moderna’s current Covid vaccine was six times less effective against the new strain.

Health secretary Matt Hancock said the government would leave “no stone unturned” in efforts to stamp out new mutations popping up across the UK.

Door-to-door testing for the South African variant launched in several parts of the country on Tuesday after a “small number” of people were found last week to be infected with the new mutation despite having no travel links. 

Residents in the London boroughs of Ealing, Haringey and Croydon received knocks on the door this week asking them to take Covid tests for the new South African variant.

Read more

Ari Emmanuel snaps up West End theatre group ATG for £4.5bn

Paddington Bear in a blue duffle coat and red hat on a purple background with BAFTA and EE logos

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business
  • Politics

Related Topics

  • Coronavirus
  • Vaccine

Trending Articles

  • As it happened: FTSE 100 drops as oil prices rise after Trump makes Hormuz threat

  • Jobless Banquet: Youth unemployment surge ‘sends Neets to KFC’

  • US bond market jitters spark UK economy recession warning

  • Monzo chair makes early exit after boardroom rift

  • Aldi boss wades into supermarket ‘price-gouging’ row

More from Morning Wire

  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Ari Emmanuel snaps up West End theatre group ATG for £4.5bn

    Hospitality
    Paddington Bear in a blue duffle coat and red hat on a purple background with BAFTA and EE logos
  • Government urged to refuse £1bn British Steel repayment to Chinese former owner 

    Politics
    Labour's Jonathan Reynolds unveiled the industrial strategy in June.
  • SailGP, rugby and PJL: Inside the new £50m budget sporting asset class

    Sport Business
    Getty Images logo on a digital screen, representing media and stock photography in a business news context
  • Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

    Business Wire
  • Currys launches £50m buyback as it shrugs off market slowdown

    Retail
    Currys storefront with prominent logo and modern exterior design, reflecting its role as a leading electronics retailer
  • Burnham set for crunch decision on JP Morgan’s £10bn tower

    Banking
    Breaking news update with relevant statistics and graphs displayed on a digital screen, highlighting recent data trends.
  • Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook